1. Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.
- Author
-
Zheng, Tony J., Parra-Izquierdo, Iván, Reitsma, Stéphanie E., Heinrich, Michael C., Larson, Mark K., Shatzel, Joseph J., Aslan, Joseph E., and McCarty, Owen J. T.
- Subjects
BLOOD platelet aggregation ,BRUTON tyrosine kinase ,PROTEIN-tyrosine kinase inhibitors ,JANUS kinases ,BLOOD platelets ,G protein coupled receptors ,CELL aggregation - Abstract
Tyrosine kinase inhibitors (TKIs) have emerged as a promising class of target-directed, small molecule inhibitors used to treat hematologic malignancies, inflammatory diseases, and autoimmune disorders. Recently, TKIs have also gained interest as potential antiplatelet-directed therapeutics that could be leveraged to reduce pathologic thrombus formation and atherothrombotic complications, while minimally affecting platelet hemostatic function. This review provides a mechanistic overview and summarizes the known effects of tyrosine kinase inhibitors on platelet signaling and function, detailing prominent platelet signaling pathways downstream of the glycoprotein VI (GPVI) receptor, integrin αIIbβ
3 , and G protein-coupled receptors (GPCRs). This review focuses on mechanistic as well as clinically relevant and emerging TKIs targeting major families of tyrosine kinases including but not limited to Bruton's tyrosine kinase (BTK), spleen tyrosine kinase (Syk), Src family kinases (SFKs), Janus kinases (JAK), and signal transducers and activators of transcription (STAT) and evaluates their effects on platelet aggregation and adhesion, granule secretion, receptor expression and activation, and protein phosphorylation events. In summation, this review highlights current advances and knowledge on the effects of select TKIs on platelet biology and furthers insight on signaling pathways that may represent novel druggable targets coupled to specific platelet functional responses. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF